The neuro-immune axis of SEMAGLUTIDE:
Why glia hold the key to CNS rescue

Newsletter # 132



In vivo and in vitro studies


The scientific community has long debated whether GLP-1 receptor agonists like Semaglutide — the active principle behind Ozempic® and Wegovy® — offer a direct shield to the brain or simply improve the metabolic environment around it.

Today, we are sharing a data-driven narrative that solves this puzzle by mapping the journey from systemic inflammation to cellular survival.

The Observation: Restoring the Mind

Our story begins with the LPS-induced cognitive deficit model, in which semaglutide acted as a cognitive "rescue," with the 0.1 mg/kg dose returning the mice to their full functional cognitive performance.


Ask for more informations

The Mechanism: Silencing the Storm

To uncover the "why" behind this recovery, we examined the cellular cross-talk between glia and neurons. In a co-culture environment under inflammatory stress, semaglutide acted as a master regulator. It protects neurons specifically by silencing the inflammatory storm, as illustrated by the inhibition of Nitric Oxide (NO) release, a key marker of glial-mediated neuroinflammation. By suppressing the formation of neurotoxic environment, Semaglutide allowed neuronal survival rates to rebound.
The Discovery: A Glial-Dependent Hero

The most revealing chapter of this story, however, came from what we didn’t see. Semaglutide’s protective effect vanished in pure neuronal cultures challenged with amyloid-beta (as shown in the graph) or glutamate-induced excitotoxicity (data not shown). This "negative" result provides our most vital insight: semaglutide is not a direct neuronal stabilizer, but a neuroimmunomodulator. Its efficacy is entirely contingent upon the presence of glia, where it acts as a "molecular brake" to prevent microglia and astrocytes from turning neurotoxic. Without this glial mediator to receive the signal, semaglutide cannot intervene, leaving the neurons unprotected against the primary toxic insult.


    The New Perspective
    These findings provide a vital bridge for reconciling the gap between preclinical promise and clinical outcomes. Our team specializes in deploying these integrated platforms to help partners move beyond indirect metabolic benefits and validate the targeted neuro-immune potential of their own pipelines. We invite you to explore this data and discuss how our specialized models can help you define the true potential of your CNS candidates.

    NEUROFIT offers a range of validated in vitro and in vivo screening tests for psychiatry and neurology.

    If you need further information, please do not hesitate to contact us, we will reply within few days. Custom protocol

    On a regular basis we distribute newsletters with scientific information on our research services. If you wish to receive these, please :